FOSUN PHARMA (02196) announced an adjustment to its 2025 A-share stock option incentive plan. Six of the initially designated grantees are no longer employed by the group and thus excluded from the incentive scheme. Following authorization by the shareholders' meeting and approval by the board of directors, along with verification by the board's remuneration and appraisal committee, the number of grantees under the initial grant was reduced from 201 to 195, and the corresponding A-share options were adjusted from 4.5809 million to 4.5351 million. On November 4, 2025, a total of 4.5351 million A-share options were granted to 195 incentive recipients at an exercise price of RMB 27.93 per share.